After a nice rise early in the day, health stocks settled back into neutral territory on Tuesday.
The Nasdaq biotechnology index landed up 0.2% while the Amex index gave up 0.2%. A few regulatory items peppered otherwise light news. Amylin (AMLN Quote) and Eli Lilly(LLY Quote) investors waited Tuesday for a 5 p.m. EDT conference call. The companies said late Monday that they would discuss a Food and Drug Administration advisory on diabetes drug Byetta.
Last week regulators warned that the drug could be linked to six cases of severe pancreatitis, two of which resulted in deaths. The FDA said it was working with the companies to add stronger warnings in the product label around the risk of necrotizing or acute hemorrhagic pancreatitis. Amylin shares were off by 53 cents, or 1.9%, at $27.24, while Lilly shares crept down 50 cents, or 1.05%, to $47.02. ...
Recent Comments
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,337.05 | 1,095.94 | 2,183.73 | 34.23 |
Oil *
72.45
|
|
UP
51.08
|
UP
4.01
|
UP
10.74
|
UP
0.31
|
10 Yr
3.42%
SPDR Gold
110.84
|
|
+0.50%
|
+0.37%
|
+0.49%
|
+0.91%
|
Data delayed 20 minutes |
Connect with TheStreet